Global in-vitro toxicology testing market size is anticipated to reach USD 30.9 billion by 2027

October 19, 2020 - The global in-vitro toxicology testing market size is anticipated to reach USD 30.9 billion by 2027 and is projected to register a CAGR of 9.2% over the forecast period. The new paradigm shift in toxicity testing of animal models toward computational methods such as silico models to interpret toxicity pathway data, drives the demand for in-vitro toxicology testing. These methods provide cost and time efficiency and enhance safety assessment.

Several governments are taking measures to minimize animal-based test models, forming conducive government policies, and providing funds to support in-vitro models. These factors are expected to create ample growth opportunities for the market. For instance, in November 2019, the U.S. National Institute for Environmental Health Sciences planned to provide funds to small companies for the development of engineered 3D culture or organotypic culture models (OCM) in-vitro systems.

In-Depth research report on In-vitro Toxicology Testing market:    
https://www.radiantinsights.com/research/in-vitro-toxicology-testing-market

With advancements in high throughput screening, biological screening, and chemical synthesis, the number of publicly available databases containing data related to toxicity; absorption, distribution, metabolism, and excretion (ADME); pharmacovigilance; and drug screening has expanded rapidly. This has enabled scientists to access vast information for toxicity profiling, thereby spurring revenue generation in this market.

Further key findings from the report suggest:

• Growing application of 3D-spheroid-cultures, particularly for nanoparticle toxicity testing, resulted in the dominance of the cell culture technology segment in 2019

• Omics technology is anticipated to register lucrative growth as RNA sequencing and shotgun proteomics are increasingly used for a more comprehensive understanding of the effects of toxicants

• The high usage rate of cellular assays with advancements in cell-based technologies, including label-free detection and high-content screening, has contributed to the dominance of the cellular assays segment in 2019

• Systemic toxicology emerged as the leading application segment in 2019 as it plays a key role in risk assessment during drug development procedures. For instance, toxicity testing of systemic immunosuppressive drugs and systemic corticosteroids is important during the development of drugs for ocular inflammatory disease

• Pharmaceutical industry dominated the in-vitro toxicology testing market in 2019 as toxicological testing is a prerequisite step for drug development

• Stringent government regulations regarding animal usage for toxicity analysis in North America have led to an increased adoption rate of in-vitro models. Hence, North America dominated the global market in 2019

• The Asia Pacific region is anticipated to witness the fastest growth rate over the forecast period due to increasing initiatives by public agencies to encourage acceptance of non-animal test models

• Abbott, Thermo Fisher, Agilent Technologies, GE Healthcare, Bio-Rad, and Merck KGaA are some of the key players operating in the market.

To get free request sample:
https://www.radiantinsights.com/research/in-vitro-toxicology-testing-market/request-sample

Protein Engineering Market to Witness Growth Acceleration During 2025

September 28, 2020 - The global protein engineering market is expected to reach USD 3.09 billion by 2025. The market is driven by presence of regulatory authorities consistently striving to reduce time and cost involved in the drug discovery process. One such example is the launch of critical path initiative by U.S. FDA, for incorporation of advanced technologies, such as protein engineering, in drug discovery processes. Moreover, this facilitates prediction of probable adverse reactions & toxicity and improves efficacy of target molecules early on, resulting in lowered drug attrition rates in the later stages. This is anticipated to help control overall expenditure. Rise in R&D expenditure by countries indicates the urgent need for adoption of these tools in all drug discovery and development processes.

In-Depth research report on Protein Engineering market:    
https://www.radiantinsights.com/research/protein-engineering-market

The rising number of government initiatives aimed at enhancing protein engineering capabilities is anticipated to present the market with high growth potential. This has resulted in a significant rise in number of research activities & programs and fund allotment for R&D. For instance, Protein Engineering Network of Centres of Excellence (PENCE) contributed approximately USD 1.0 million for proteomics projects and hosted conferences on proteomics in Canada as an effort to broaden research associated with this technology.

Further key findings from the report suggest:

• Hybrid approach is predicted to observe exponential growth as a consequence of technological superiority and ability to overcome the shortcomings associated with the aforementioned technologies

• Software & services is expected to emerge as the fastest growing segment owing to high inclination of companies to outsourcing of services to achieve overall cost-efficiency

• Monoclonal antibodies held the largest share in protein-type segment due to development of these antibodies on a large scale through extensive adoption of these engineering tools

• North America held a substantial share, which can be attributed to extensive research activities that are likely to provide high potential growth platform through consistent usage in this region

• The market in Asia Pacific is projected to exhibit exponential growth over the coming years owing to rising awareness pertaining to benefits of protein engineering and increasing disposable income

• The competition is marked by players employing strategies such as mergers & acquisitions and distribution agreements resulting in significant growth in their market share.
  

To get free request sample:
https://www.radiantinsights.com/research/protein-engineering-market/request-sample

A maturing and strongly diversified clinical pipeline is expected to contribute to the growth of stem cell market

September 18, 2020 - The global stem cell market size is expected to reach USD 15.63 billion by 2025, at a CAGR of 8.8% during the forecast period. Amplifying research studies targeted at widening the utility scope of stem cell products is anticipated to drive the growth. These research projects are set to offer new opportunities for implementation of several clinical applications of stem cells. Thus, extensive research on exploring varied applications of stem cells would impact treatment options that aid in disease-modification.

In addition, collaborations targeted at achieving robust manufacturing of high-quality differentiated cells is expected open up new avenues of market expansion over the forecast period. Rapid transition from conventional treatment methods to regenerative medicine has been observed over the past few years. Regenerative medicine is set to become the new prototype of treatment in human health having the potential to address unmet medical needs across the globe. Integration of biologics, chemical compounds, materials, and devices is witnessed in stem cell therapeutics making it an interdisciplinary field.

Browse full research report:
https://www.radiantinsights.com/research/stem-cell-market

Moreover, rising recognition of cellular therapies as an emerging revolutionary advancement has been witnessed in the healthcare industry in recent years. Business expansion is adopted by companies aiming at strengthening their portfolio regarding cellular therapy. This is expected to improve detailed understanding and future potential of stem cells for the of patients suffering from Parkinson's disease, diabetes, injuries associated with spinal cord, and other neurodegenerative disorders.

Further, a maturing and strongly diversified clinical pipeline is expected to contribute to the growth of stem cell market. Availability of latest data during the mid and late stage of the regenerative medicine clinical trials and increase in the product approvals regarding the same is expected to drive the market.

Adult stem cells displayed highest contribution in the market and is expected to maintain its dominance over the forecast period. Factors such as minimal ethical issues, lower rejection rates, and long-term renewal property associated with stem cells utility has contributed to the dominance of this segment. Moreover, the characteristic property of these cells to regenerate into malignant cells is anticipated to support the estimated share.

Scientists at Michigan State University revealed novel type of cells, named induced XEN cells, originated from a cellular trash pile in March 2016. The conclusions drawn from this research study is expected to drive emerging regenerative medicine treatment methods. In January 2019, research professionals at the University of Freiburg carried out research on the potential of mesenchymal stems cells in repairing damaged organs. This is further anticipated to boost research as well as sales in the market throughout the study period.

Further key findings from the report suggest:

• Based on application regenerative medicine is estimated to hold a substantial market share in terms of revenue over the forecast period, owing to rise in emerging pipeline projects

• Progress of acquisition technology is expected to gain momentum during the forecast period owing to the rising research projects that demand the use of harvesting techniques

• Amongst the type of therapies used, autologous therapy accounted for the largest share of the stem cell market

• Likelihood of getting new infections is less in autologous cell-based therapy, consequently enhancing its adoption

• R&D activities carried out on large scale and huge funds granted by funding bodies to advance cellular research in U.S. have made North America the dominant region in the global market

• Vast research studies taking place in Singapore and Japan is anticipated to propel the Asia Pacific market in the forthcoming years

• Osiris Therapeutics Inc.; Celgene Corporation; BIOTIME, INC.; Cynata; Advanced Cell Technology Inc.; and STEMCELL Technologies Inc.; are some of the key market players

• The companies are undergoing strategic partnership to enhance their product line. They are keen on seeking investments from overseas organizations along with adopting partnership strategies with pharmaceutical organizations, which is set to fuel the market growth.

Download free request sample:
https://www.radiantinsights.com/research/stem-cell-market/request-sample

Research Antibodies Market Analysis By Type (Monoclonal, Polyclonal) and Forecasts to 2027

Feb 26, 2020 - The global research antibodies market size is expected to reach USD 5.6 billion by 2027, exhibiting a CAGR of 6.2% over the forecast period. Major market drivers include rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, growing interest in the study of neurobiology and stem cell, availability of technologically advanced products, and strategic collaborations among various market players and academic research organizations.

Designer antibodies are also anticipated to attract the attention of various academic organizations for their use in the R&D of novel products. For instance, in April 2019, scientists from ALS Canada Research Program developed a set of antibodies that can help in the detection of misfolded TDP-43 in various lab experiments that utilize post-mortem brain tissues. Rising usage of research antibodies for the development of novel diagnostic therapies is thus anticipated to fuel market growth in the near future.

In-Depth research report on Research Antibodies market:   
https://www.radiantinsights.com/research/research-antibodies-market

Increase in the usage of research antibodies to develop treatment options for various diseases is also expected to boost market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid in the understanding of various aspects of virus pathogenesis, entailing further research on antiviral therapies. Growing government funds and initiatives for R&D is anticipated to fuel the Asia Pacific market during the forecast period. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, rise in funds invested by pharmaceutical and biotechnology companies to enhance the study of proteomics and genomics is expected to drive the market. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. Rise in the number of major market players investing in advanced technologies and collaborating with other market players is also anticipated to positively impact market potential in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and to discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies.

North America dominated the research antibodies market in owing to increasing focus on R&D in the fields of biomedicine, stem cell, and cancer. Rising prevalence of chronic diseases such as cardiovascular and blood diseases is also expected to fuel market growth.

Launch of novel antibody structures for diagnosis of various diseases is also a major factor expected to boost the market. For instance, in August 2018, BioGenex launched a range of new antibodies for its use in cancer immunohistochemistry. The company’s immunohistochemistry solution offers about 400 reagents, primary antibodies, consumables, and ancillaries.  Key players in the market include Abcam Plc; Bio-Rad Laboratories Inc.; PerkinElmer, Inc.; Agilent Technologies; Roche; Cell Signalling Technology, Inc.; Thermo Fisher Scientific; Lonza Group; and BD.

Further key findings from the report suggest:

• By product, primary antibodies held the dominant share in 2019 in terms of revenue owing to greater specificity, therefore leading to increased adoption in R&D activities         

• Based on type, monoclonal antibodies captured a substantial market share in 2019 as they offer higher sensitivity for detection of antigens and also showcase efficient staining properties for various applications

• The Western blotting technology segment has witnessed exponential growth owing to increasing prevalence of diseases with limited treatment options and rise in R&D activities conducted by pharmaceutical and biotechnology companies and academic institutes

• Based on end use, pharmaceutical and biotechnology companies were dominant in terms of revenue in 2019 owing to increased adoption of research antibodies in drug development and discovery

• North America accounted for a substantial share of the research antibodies market in 2019, which is attributable to high presence of many biotechnologies as well as biopharmaceutical manufacturers, research academies, and laboratories.

To get a free sample request at:
https://www.radiantinsights.com/research/research-antibodies-market/request-sample

Advancements in genomics and associated technologies has significantly impacted crop genetics

The global genomics market is expected to reach USD 27.6 billion by 2025. The past decades have witnessed significant changes in disease management processes due to simultaneous advancements in genomics and personalized medicine. There has been a gradual growth in the usage of genomic studies in clinical practices, which is reflected by the growing trend of targeted therapies.

Results from genomic studies enable a better understanding of diseases and the underlying mechanisms for researchers, physicians, and consumers. This facilitates evidence-based decision-making, and hence, helps improve personalized treatment regime. In addition, technological advancements in data analysis tools have motivated healthcare community to create precision-based therapies from surplus, available DNA data.

Advancements in genomics and associated technologies has significantly impacted crop genetics. Technological advancements in sequencing facilitates genomes & transcriptomes sequencing for several crops. Although a reference genome exists for several crops, resequencing and gene expression studies are required for in-depth study of key genes contributing to the desired trait. Implementation of this information in crop breeding helps in development of advanced crops.

Download free request sample : www.bit.ly/2Nfr9fx

 
The companies are involved in strategic alliances with global as well as local entities to boost their revenue generation and enhance their share in the market. For instance, in March 2017, Foundation Medicine collaborated with Bristol-Myers Squibb Company, as a result of which Bristol-Myers Squibb could deploy Foundation Medicine's molecular information solutions and comprehensive genomic profiling for identification of predictive biomarkers, such as Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB), to accelerate its immunotherapy clinical trials. Such initiatives are aimed at increasing the adoption of genomic information in cancer management.

Further key findings from the report suggest:

• High volume requirement and the high cost of specific reagents contribute to substantial revenue share. Companies are embracing the trend of offering varied reagents that simplify workflow process

• NGS-based services held a major share in the genomics services segment due to its rapid adoption of whole genome sequencing and application of sequence databases for disease screening and prognosis

• NGS-based services have witnessed a continuous growth since its introduction

• The demand for these services would remain strong with the expansion of the customer base from being limited to academic and research centers to CROs, biotech and pharma players.

• Biomarkers exhibit high clinical potential and efficiency across treatment of wide range of diseases

• Use of predictive biomarkers for diagnosis and monitoring take cancer eradication a step further. Moreover, organizations and programs such as National Biomarker Development Alliance (NBDA) are actively participating in development of novel biomarkers for cancer diagnosis

• Thus biomarkers are expected to exhibit the fastest growth in the coming years over the forecast period

• The growing interest of pharmaceutical and biotechnology companies in genomics is expected to drive market growth in the coming years.

• As patients are focusing on their health, Direct-To-Consumer (DTC) laboratory testing is increasingly being employed. DTC genetic tests enable consumers to access information about their genetics without necessarily including healthcare professionals in the process.

• A few emerging and established companies are competing in this space

• Asia Pacific is the most potential region and an emerging market for genomics. This market is anticipated to grow at the highest CAGR of 12.7%.

• Developing infrastructure in these countries has led to the increased demand for biomarkers for diagnostics purposes.

• Major players include BGI; Agilent Technologies; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc; Foundation Medicine, Inc, 23andMe, Inc, Danaher, Illumina, Inc; Pacific Biosciences; Oxford Nanopore Technologies.; F. Hoffmann-La Roche Ltd., and Myriad Genetics, Inc.

Visit for more : www.bit.ly/2KSF0vq

Frozen non-donor is identified as the most lucrative procedure segment of the assisted reproductive technology industry

The global assisted reproductive technology (ART) market is expected to reach USD 45 billion by 2025. Childbearing postponement is one of the high impact rendering drivers of the infertility treatment market. The reproductive behavior and pattern of some of the nations such as few European nations have shifted from early to late childbearing pattern.

Increasing marital age, rising tobacco and alcohol consumption, increasing obesity rate are some of the other factors contributing to the market growth. Furthermore, increasing incidence rate of conditions such as poly-cystic ovarian syndrome (PCOS), tubal factors and endometriosis are other drivers of the market.

According to the Society for Assisted Reproductive Technology, 2012 was the year with highest percentage of babies born through IVF treatment. The treatment has become more successful and has gained more acceptance, which is further expected to increase the market size in the coming years.

Further key findings from the report suggest:

• Fresh non-donor was the largest ART market procedure segment in 2014. The fact that fresh eggs and sperms increase the number of successful pregnancies is expected to drive segment growth over the forecast period.

• According to a recent study published in the New England Journal of Medicine.by the researchers from Vietnam and China, frozen embryos are not more effective in comparison to the fresh embryos for all women, specifically those suffering from PCOS.

• Frozen non-donor is identified as the most lucrative procedure segment of the assisted reproductive technology industry. A new study claims that the fertility treatment with frozen embryos may have more probability of success than those performed with fresh embryos.

• IVF with ICSI dominated the technology type market segment owing to increase in the chances of successful fertilization, and exceptional technique for treating male infertility. As per the study published in fertility journal Human Reproduction Update 2017, North America, Europe, New Zealand and Australia, men's sperm counts declined by 50-60% over the period between 1973 and 2011. Changing lifestyle and environmental factors are some of the factors responsible for the decline of sperm counts.

• Frozen embryo replacement (FER) is anticipated to grow at a rapid rate over the forecast period owing to the fact that in the clinics fresh embryos are used first and only good quality and spare embryos are transferred at a later stage. The trend is to transfer single embryos rather than risking by transferring two or more embryos. This is expected to increase the FER segment market in the coming years.

• Europe dominated the market and is anticipated to maintain its dominance during the forecast period The Asia Pacific region is likely to witness significant growth over the next decade due to improving healthcare infrastructure, increasing awareness and adoption of IVF procedures.

• Technological advancements is expected to drive the market in the coming years. In 2016, INVO Bioscience, Inc. announced the FDA approval of first intravaginal culture system, INVOcell, wherein women's vagina is used as a natural incubator and the clinical trials have produced pregnancy similar to traditional IVF treatments

• Some of the key players are California Cryobank, Bloom IVF Centre, Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck KGaA, Ferring Pharmaceuticals, Boston Science Corporation and Hamilton Throne Ltd.

Free request sample : www.bit.ly/2NtV2cL

Read full details : www.bit.ly/2Kzxzcf

Liquid Biopsy Market Size By Application, Sample Type, Biomarker Type,Technology, Region, And Forecasts to 2030

The global liquid biopsy market size is expected to reach USD 5.96 billion by 2030, exhibiting a CAGR of 13.4% during the forecast period. Enhanced view of tumor provided by liquid biopsy technology is estimated to augment the market in coming years.

While tissue biopsies have been standard for cancer diagnosis for past several year, their highly invasive nature and frequently associated complications have been major concerns. Moreover, these biopsies lead to high expenditure being incurred by patients. Liquid biopsies, on the other hand, offer a less invasive methodology along with high effectiveness. Thus, there are a number of key private organizations involved in rigorous R&D activities for liquid biopsy test development and it is only a matter of time before these procedures grow in prominence in diagnostic paraphernalia of oncologists and pathologists.

Further key findings from the report suggest:

• Technological developments such as electric field induced release and measurement (EFIRM)- Liquid Biopsy (eLB), which provides detection that can assist clinical treatment decisions for most common subtype of cancers are expected to drive the uptake of saliva based sampling over the forecast period

• Currently, clinical use of isolation and detection technology is limited to CTC quantitation but the number of CTCs is found to hold significant correlation with disease severity. This is, thus, estimated to augment the market over the coming years

• Rising awareness regarding advantages of multiple gene analysis along with the help of NGS is anticipated to support the growth of the market

• Organizations such as American Society of Clinical Oncology (ASCO) are engaged in supporting implementation of liquid biopsy, which in turn is likely to spur the growth of the market

• Intensifying competition between biotech companies and increasing investments by government in healthcare institutes will lead to development of more sophisticated tests

• Companies engaged in R&D and commercialization of these products include Pathway Genomics; Natera Inc.; Epic Sciences; Illumina; Foundation Medicine; Roche; LabCorp; and Sequenom

Request free sample : www.bit.ly/2tSMbcn

Browse full research report : www.bit.ly/2MM8qrC

Toxicological testing is the pre-requisite step in the development of any pharmaceutics and cosmetic products

The global in-vitro toxicology testing market size is expected to reach USD 26.98 billion by 2025, progressing at a CAGR of 11.4% during the forecast period. Technological advancements in computational biology along with introduction of novel efficient algorithms help in conduct of efficient stimulation of in-silico animal models. This, in turn, has significantly curtailed the need for animal models for clinical studies, thereby providing a fillip to the market.

To get more details :
https://www.radiantinsights.com/research/in-vitro-toxicology-testing-market

Furthermore, scientists are increasingly engaging in enhancing the efficiency of databases that are designed to catalog vast information for toxicity profiling. This, in turn, is anticipated to create ample growth opportunities for the market during the forecast period.

Growing inclination of government toward non-animal test and consequent establishment of guidelines on the use of alternative test assays for pre-clinical research and toxicology testing is expected to bolster the adoption of in-vitro toxicological tests.

Further key findings from the report suggest:

• The pharmaceutical and cosmetic industries represented considerable cumulative share in 2016. As toxicological testing is the pre-requisite step in the development of any pharmaceutics as well as cosmetic products, these segment held the largest share

• Cell culture technology is estimated to be the largest segment in terms of revenue owing to integral role of cell culture in clinical studies

• Omics technology is anticipated to exhibit the highest CAGR during the forecast period. Rising awareness regarding the merits of the technology such as high accurate and rapid toxicology assessments is supplementing the growth of the segment

• On the basis of application, cellular assays held the leading share in the market owing to constant development in cell culture techniques

• North America dominated the market in 2016. On the other hand, Asia pacific is expected to register a noteworthy CAGR during the forecast period

• Rapid advancements in health care infrastructure coupled with improving economic conditions in Asian countries are expected to drive the market in APAC

• Some of the key participants in the market are Abbott; Bio-Rad Laboratories; and Thermo Fisher Scientific, Inc. These participants are engaged in collaborations with clinical research organizations and pharmaceutical industry.

Download sample request :
https://www.radiantinsights.com/research/in-vitro-toxicology-testing-market/request-sample

Transfection Reagent And Equipment Market is is Expected to Reach $ 1.08 Billion by 2022

The global transfection reagent & equipment market size is expected to reach USD 1.08 billion by 2022, progressing at a CAGR of 7.4% during the forecast period. The growth of the market can be attributed to ongoing oncology-based research & development that aimed at understanding disease cause at genomic & molecular levels coupled with consequent surging demand for targeted therapies.

Browse full research report :
https://www.radiantinsights.com/research/transfection-reagents-and-equipment-market

Transfection technology is recognized as an integral part of research programs pertaining to thorough investigation of various chromosomal anomalies. Hence, rising cancer prevalence of cancer as well as genetic conditions is anticipated to provide a fillip to the market. Furthermore, funds and grants by funding and government bodies are likely to back the growth of the market.

Funding and federal agencies, such as National Science Foundation (NSF), are offering the biotechnology sector with huge funding to carry out their biotechnology-based investigational studies. Moreover, international funding bodies such as NIH and Welcome Trust are projected to play a crucial role in the growth of the market by providing funds for genetic research studies. Such significant funds and grants are poised to boost the adoption of transfection technology over the forecast period.

To Read more reports of this category
https://www.radiantinsights.com/catalog/biotechnology

Further key findings from the report suggest:

• On the basis of method, electroporation and liposomal transfection accounted for substantial cumulative share in the market. Several advantages offered by these techniques over other methods in terms of timeliness, complexity, and variability are supplementing the growth of the segment

• Transfection technology serves a wide range of applications with gene expression studies being the largest application in terms of revenue in 2016

• North America was the most prominent regional market in 2016. The growth of the region can be attributed to presence of prominent participants coupled with well-established biotechnology & genomic industries

• Asia Pacific is estimated to post a noteworthy CAGR during the forecast period owing to increasing investments by international players for business expansion and rising buying power of consumers

• Thermo Fisher Scientific Inc.; Promega Corporation; QIAGEN; and F.Hoffmann-La Roche Ltd are some prominent players in the market. These companies are undertaking several endeavors to enhance their shares in the market

Request free sample : 

https://www.radiantinsights.com/research/transfection-reagents-and-equipment-market/request-sample

Next-Generation Sequencing (NGS)-based IVD Systems to Emerge Vital Research Tools in Clinical Applications

Next-generation sequencing (NGS) is a DNA sequencing technology, which has emerged as a vital element in genomic research. It is gaining prominence as an everyday research tool among researchers to study biological systems at a more rapid pace than conventional sequencing methods such as Sanger sequencing.

Read full research report at :

https://www.radiantinsights.com/research/global-next-generation-sequencing-ngs-market-report-and-forecast-to-2021

 
Utilization of the NGS technology in IVD systems for clinical applications is likely to witness a sharp rise. For instance, in November 2017, Illumina, Inc. announced the launch of its NextSeq™ 550Dx instrument, a CE-IVD marked and FDA-regulated NGS system for the development of an array of IVD assays.

Lower Turnaround Time to Make Targeted Sequence a Highly Preferred Product

Next-generation sequencing is used to describe a number of different modern sequencing technologies, including targeted sequencing, transcriptome sequencing, and exome sequencing. Demand for targeted sequence is likely to remain high for coming years. Declining sequencing costs and rising awareness regarding its advantages such as manageable data sets and lower turnaround time can contribute to the growth of the segment. Increasing number of projects being undertaken pertaining to protein expression analysis is translating into the greater uptake of targeted sequencing. Soaring need for analysis of smaller dataset can also supplement the growth of the segment.

Adoption rate of exome sequencing is likely to increase at a noteworthy pace in the near future. The growth of the segment can be attributed to rising research and development activities aimed at mapping human and non-human genomes. Uptake of exome sequencing is high for the study of rare Mendelian disorders as it is an effective way to detect genetic variants in the genes of an individual. Rapid technological advancements will also benefit the growth of the segment.

Market Insights

Increasing efforts by companies to boost awareness regarding NSG services and products through workshops and seminars can escalate the growth of the next-generation sequencing (NGS) market. Rising R&D activities promoting advancements in the field of metabolomics, transcriptomics, and proteomics are likely to provide a fillip to the market. Genomics and proteomics operate with the help of extensive structural information that needs to be gathered and arranged by means of determination of sequence and subsequent integrated data analysis.

As per the findings of a report added to Radiant Insights, Inc.; Asia Pacific is likely to remain a promising region during the forecast period (2017 to 2021). Improving healthcare infrastructure is anticipated to drive the market in the region. Some of the prominent companies in the market are CapitalBio Corporation, Thermo Fisher Scientific, Berry Genomics Co. Ltd., Roche, and Qiagen.

To get free sample request at :

https://www.radiantinsights.com/research/global-next-generation-sequencing-ngs-market-report-and-forecast-to-2021/request-sample

Flow Cytometry Market Structure, Strategies and Application to 2025

The global flow cytometry market is expected to reach USD 8.0 billion by 2025. The increasing incidence of infectious diseases and cancer is expected to upsurge the demand for flow cytometers for use in disease diagnosis over the coming years.

In addition, higher number of physicians is inclined toward the usage of autologous and allogenic stem cell therapy, due to adverse effects caused by chemotherapy & radiation therapy in the treatment of cancer, thereby affecting the growth of this market.

Moreover, rising demand for point-of-care testing in chronic diseases management is expected to fuel the demand for cytometry techniques.

Rising implementation of microfluidic miniature flow cytometry in point-of-care diagnostics is the factor augmenting the future growth. Increasing R&D initiatives by various key players for the development of multicolor assays and advanced reagents for analysis are anticipated to boost the usage rate.

Advancement in technology for the purpose of enhanced accuracy, portability, and cost-effectiveness is expected to serve this market with lucrative growth opportunities.

Small-size high-throughput cytometers are expected to gain popularity over the coming years due to associated benefits such as ease in use and cost-effectiveness.

Furthermore, improvement in fluorescent dyes & introduction of bench top cytometers are the other growth propellers. For instance, multicolor flow cytometry coupled with multiple lasers is the fastest growing application segment, which finds extensive applications in the field of R&D innovations in new drug development and is adopted by many contract research organizations.

Further Key Findings from the Study Suggest:

• Bead-based flow cytometry is anticipated to witness lucrative growth rate over the forecast period owing to increasing advancement in molecular engineering & monoclonal antibody production

• Reagents & consumables are expected to be the fastest growing segment as of 2016 due to extensive utilization in molecular diagnostics

• Clinical diagnosis market is driven by factors such as increasing demand for cost-effective disease diagnosis and associated benefits of these assays in disease detection

• The largest market share of commercial organizations can be attributed to the rising large-scale production of proteins, cell line development, and other biologicals coupled with the growing demand for cell sorting and analysis techniques

Request free sample at:
http://www.radiantinsights.com/research/flow-cytometry-market/request-sample

• Asia Pacific regional market is presumed to witness the fastest growth owing to increasing supportive government initiatives for flourishing biotech industry coupled with growing awareness about the applications of flow cytometers

• Multinational players collaborating with local diagnostic companies and healthcare institutions in developing countries such as India & Brazil, target the disease population and are expected to increase market penetration